EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials

Christopher Gottschalk, Pranav Gandhi iD, Patricia Pozo-Rosich iD, Suzanne Christie, Cristina Tassorelli iD, Jonathan Stokes, Yingyi Liu, Lei Luo, Krisztian Nagy, Joel M Trugman, Richard B Lipton iD

Cephalalgia · 2024

DOI: 10.1177/03331024241300305 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cephalalgia, 2024. Verfasst von Christopher Gottschalk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Yale Medicine Department of Neurology, New Haven, CT, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Quality of Life. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to assess the effects of preventive migraine treatment with atogepant vs. placebo on patient-reported quality of life and functioning.

Methods

Analyses of patient-reported outcomes from three 12-week, randomized, placebo-controlled trials evaluating preventive migraine treatment with atogepant 60 mg once-daily: ADVANCE (low-frequency episodic migraine [LFEM], 4–8 monthly migraine days [MMDs] and high-frequency episodic migraine [HFEM], 8–14 MMDs), PROGRESS (chronic migraine, CM) and ELEVATE (episodic migraine in those previously failed by two to four classes of oral preventive treatments).

Results

Least squares mean differences (95% confidence interval (CI)) in change from baseline were greater ( p < 0.05) for atogepant vs. placebo for Migraine-Specific Quality of Life questionnaire Role Function–Restrictive domain scores at week 12 (ADVANCE: LFEM 12.0 (95% CI = 6.0–18.0), HFEM 9.9 (95% CI = 3.4–16.4); PROGRESS: 6.2 (95% CI = 2.5–9.8); ELEVATE: 17.7 (95% CI = 13.1–22.3)), for Headache Impact Test-6 total scores at week 12 (ADVANCE: LFEM −4.7 (95% CI = −6.7 to −2.7); HFEM −3.4 (95% CI = −5.5 to −1.2); PROGRESS: −2.8 (95% CI = −4.1 to −1.4); ELEVATE: −6.5 (95% CI = −8.3 to −4.7)) and for Activity Impairment in Migraine–Diary-Performance of Daily Activities scores across 12 weeks (ADVANCE: LFEM −2.3 (95% CI = −3.9 to −0.7), HFEM −4.5 (95% CI = −6.9 to −2.2); PROGRESS: −3.4 (95% CI = −5.3 to −1.5); ELEVATE: −4.7 (95% CI = −6.4 to −3.1)).

Conclusions

Preventive migraine treatment with atogepant 60 mg once-daily vs. placebo improved measures of migraine-related quality of life and functioning among participants with different headache frequencies and histories of previous treatment failure. Trial Registration: ClinicalTrials.gov: NCT03777059 (ADVANCE); NCT03855137 (PROGRESS); NCT04740827 (ELEVATE)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersQuality of LifeHumansMaleDouble-Blind MethodFemaleAdultMiddle AgedActivities of Daily LivingTreatment Outcome

Stichwörter der Autor:innen

atogepantheadachemigraine disorderspatient-reported outcome measuresquality of life

Autor:innen und Institutionen

  • Yale Medicine Department of Neurology, New Haven, CT, USA.
  • AbbVie, North Chicago, IL, USA.
  • Headache Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • University of Ottawa, Neurology, Ottawa, ON, Canada.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

ORCID-Profile: Pranav Gandhi, Patricia Pozo-Rosich, Cristina Tassorelli, Richard B Lipton

Förderung

  • AbbVie

Zitieren

APA

Gottschalk, C., Gandhi, P., Pozo-Rosich, P., Christie, S., Tassorelli, C., Stokes, J., Liu, Y., Luo, L., Nagy, K., Trugman, J. M., & Lipton, R. B. (2024). Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials. Cephalalgia. https://doi.org/10.1177/03331024241300305

Vancouver

Gottschalk C, Gandhi P, Pozo-Rosich P, Christie S, Tassorelli C, Stokes J, et al. Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials. Cephalalgia. 2024. doi:10.1177/03331024241300305

BibTeX
@article{Gottschalk2024,
  author = {Gottschalk, Christopher and Gandhi, Pranav and Pozo-Rosich, Patricia and Christie, Suzanne and Tassorelli, Cristina and Stokes, Jonathan and Liu, Yingyi and Luo, Lei and Nagy, Krisztian and Trugman, Joel M and Lipton, Richard B},
  title = {Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241300305}
}
Kostenlos starten →